Curative Ventures is a capital and talent partner to category-defining biotech companies that are developing new therapies to dramatically improve patient outcomes.
Recent Investments
Press Releases
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. [...]
Vertex Enters Duchenne Therapy Market with $1B Acquisition of Exonics
Move over, Sarepta Therapeutics, Solid Biosciences, PTC Therapeutics and [...]
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline Acquisition [...]
Peloton Therapeutics Secures $150 Million in Series E Financing
- Proceeds to advance oral HIF-2α inhibitor, PT2977, into [...]
TCR2 Therapeutics Prices IPO Of 5 Mln Shares At $15.00/shr
(RTTNews) Feb 13, 2019 - TCR2 Therapeutics Inc. (TCRR) said [...]
iTeos Therapeutics Completes $75 Million Series B Financing
- Oversubscribed financing round led by new U.S. investor MPM [...]
Contact Us
Curative Ventures
info@curativeventures.com
Address
3963 Maple Avenue, Suite 390
Dallas, TX 75219